Background: Febrile neutropenia (FN) is a potentially life-threatening complication following chemotherapy. The incidence and mortality of this condition varies according to cancer type and chemotherapy regimen. The aim of the study was to establish the incidence, risk, outcome, infectious cause and economic cost of FN in solid tumour patients within a routine oncology hospital setting.
introduction
The survival of patients with solid tumours has steadily improved over the last few decades. This is attributed to various factors including early diagnosis and better surgical and medical treatment approaches. Despite the advances in biological therapy, cytotoxic chemotherapy remains one of the key therapeutic options in the adjuvant and palliative setting of cancer treatment. One of the main complications of cytotoxic chemotherapy is febrile neutropenia (FN), which can lead to life-threatening adverse events such as severe sepsis, a subsequent delay in further chemotherapy with possible dose reductions and potentially compromised survival.
Antibiotic and granulocyte-colony stimulating factor (G-CSF) prophylaxis as well as empirical treatment protocols have been shown to improve the management of FN patients specifically where neutropenia is predictable [1, 2] . Nevertheless, over the last few years, there has been a 60% increase in the use of chemotherapy in England which means patients continue to be at risk of FN during the course of their treatment [3] .
In addition to the morbidity and mortality associated with FN, treatment delays and dose reduction are common in the remaining cycles of the chemotherapy course with potential compromise of the treatment outcome especially in patients undergoing therapy with curative intent [4, 5] . The economic cost of managing a potentially preventable FN hospital admission poses an additional burden to health care providers.
We undertook a 12-month prospective study to assess the incidence, infective cause, appropriate antibiotic use, outcome, FN risk stratification and economic cost of FN in patients with solid tumours admitted to a regional cancer centre in the UK.
patients and methods
In 2007, we carried out a prospective observational FN study at the Regional Cancer Centre of the Norfolk and Norwich University Hospital (NNUH), which has an oncology inpatient admission rate of 1700 patients per year. Over a 12-month period, all adult (≥18 years of age) oncology patients (defined as those suffering from solid tumours, head and neck cancers or melanomas) presenting with FN to the hospital were identified and included in the study to establish incidence, infective cause, appropriate antibiotic use, outcome, FN risk stratification and economic cost. Excluded were patients diagnosed with haematological malignancies.
Demographic data on age, gender, underlying cancer, disease burden [6] , co-morbidities (including diabetes, chronic obstructive airway, heart, liver and kidney disease), recent chemotherapy regimen, antibiotic treatment, history of recent invasive fungal infection, G-CSF treatment and length of hospital stay were recorded by the investigators.
FN was defined as a tympanic membrane temperature of ≥38°C for ≥1 h or a single temperature of ≥38.3°C accompanied by neutropenia ≤1 ×s 10 9 /l [1] . C-reactive protein (CRP; normal value ≤ 4 mg/l) was established as a marker of inflammation/infection. The presence of hypotension (systolic blood pressure < 90 mmHg) and dehydration was recorded on admission.
The Multinational Association for Supportive Care in Cancer (MASCC) risk index was calculated as previously defined and relates to the risk of complicated FN [6, 7] . This points based risk score (maximum of 26) was established according to patients characteristics including burden of illness (mild = 5; moderate = 3), absence of hypotension = 5, absence of COPD = 4, no previous fungal infection = 4, absence of dehydration = 3, outpatient status at onset of fever = 3 and age <60 years = 2. The score was aimed to classify patients into low FN risk (≥21 points) or high FN risk (<21 points) patients.
Clinical specimens for microbial investigation (blood culture, urine, sputum, faeces and wound swabs) were taken depending on the clinical and radiological suspicion of the focus of infection. Specimens were processed according to standard operating procedures (Health Protection Agency, Colindale, UK) in the Microbiology Department of the NNUH.
Appropriate empirical antibiotic management was audited and compared with the local NNUH guideline for the empirical treatment of FN: first-line piperacillin/tazobactam (4.5 g/8 h) in combination with gentamicin (5 mg/kg/day) or piperacillin/tazobactam alone in cases of renal impairment. Second line (if penicillin allergic) ceftazidime (1 g/8 h) or meropenem (1 g/8 h). G-CSF (filgrastim 300 μg) was reserved for severe neutropenia (≤0.5 × 10 9 /l). Chemotherapy regimens preceding the FN episode were recorded for each patient and categorised into regimens associated with low (<10%), medium (10%-20%) or high (>20%) risk of inducing FN according to European Organisation for Research and Treatment of Cancer (EORTC) guidelines [8] .
The outcome was measured as crude mortality (total number of all deaths) or attributable mortality, where the cause of death was primarily due to infection judged on clinical and laboratory parameters.
The crude cost of an FN admission was calculated on the basis of antibiotics and G-CSF used for each patient as per daily-defined doses (DDD) and on the hospital length of stay (LOS). The specific DDD's were calculated using the World Health Organisation collaborating centre for Drug Statistics Methodology online index [9] . The cost per DDD was determined using the generic cost prices given in the British National Formulary September 2007 [10] . The cost of the length of hospital stay was based on the Unit Costs of Health and Social Care 2007 document to evaluate a price for a single bed day as an inpatient [11] .
Statistical analysis was carried out with SPSS version 15 (SPSS, Woking, UK). Single predictor variable analyses were carried out using Chi-squared or Fisher's extract tests. A P-value of <0.05 was considered significant.
The study was fully approved by the NNUH Audit Committee (Norwich, UK).
results
During the 12-month study period, a total of 32 oncology patients were admitted with FN. This equates to an incidence of 19.4% of FN cases per 1000 oncology admissions. The average age was 63 years (range 25-80 years), with 56% of patients being female. The majority of patients (71.9%) were at least 60 years old or over ( Table 1 ). The mean hospital LOS was 9.2 days with a range from 1 to 24 days. The most common underlying cancer types were breast cancer (28.1%), lung and oesophageal cancer (15.6%, respectively) as well as ovarian cancers (12.5%) followed by other malignancies ( Table 1) .
The majority of patients suffered severe neutropenia with a mean neutrophil count of 0.43 × 10 9 /l (range 0.01 to 1 × 10 9 /l) and up to 90% of all patients had a raised CRP (average 117 mg/l).
Based on clinical, microbiological and radiological examination, 59.4% (19/32) of all patients presented with signs and symptoms of a specific focal infection. These included 25% (8/32) respiratory tract infections, 21.9% (7/32) gastrointestinal illnesses such as diarrhoea or peritonitis, 6.3% (1/32) urinary tract infections and 6.3% (1/32) central vascular line sepsis. In the other 40.6% of cases, patients presented with rigors and fever only without specific signs or symptoms of a defined focal infection. Only 16.1% of patients had positive The audit of the antibiotic management of FN showed that 90.6% (26/32) of patients received appropriate first-line empirical antibiotic treatment with piperacillin/tazobactam and gentamicin in keeping with the local hospital guideline. Three patients received piperacillin/tazobactam monotherapy because of renal failure and in 9.4% (3/32) of cases, patients did not receive any antibiotics in keeping with this treatment policy. These were patients diagnosed with community-acquired chest infection (receiving amoxicillin and clarithromycin) or those with diarrhoea (receiving oral metronidazole for suspected C. difficile infection). Six patients (18.8%) were on empirical antibiotics and two patients (6.3%) received antibiotic prophylaxis before admission to the hospital. Each patient received on average a total of 13.54 DDD's of antibiotics during the hospital admission.
The crude mortality among the 32 FN patients was 18.6% with an attributable mortality of 12.5% when adjusted for infection and or sepsis being the main cause of death ( Table 1 ). The majority (83.3%) of patients who died were aged ≥60 years with an average neutrophil count of 0.27 × 10 9 /l ( Table 2) . They also had a more severe disease burden and presented more commonly with hypotension compared with those patients who survived (Table 2) .
Two deaths occurred in patients receiving appropriate empirical FN antibiotic combination treatment with piperacillin/tazobactam and gentamicin (2/26), whereas four patients (4/6) who did not receive this combination died, resulting in a significant higher mortality (P = 0.004). On assessing the overall severity of FN in individual patients according to MASCC risk index, all patients who died were high-risk FN patients with an average of 16.6 MASCC risk index score versus 21.9 in those who survived (Table 3) .
A number of patients had underlying co-morbidities (34.4%) such as chronic heart disease, renal failure or diabetes mellitus but there was no significant difference in mortality compared with those patients without co-morbidities (P = 0.3). Seven patients received G-CSF (doses ranging from one to six per patient) as part of the management of severe neutropenia including two patients who died. There was no difference in survival in those patients receiving G-CSF compared with those who did not (P = 0.1). None of the 32 patients had prophylactic G-CSF before developing FN.
All patients had received chemotherapy before developing FN. A number of different combinations of chemotherapy regimens were used with the majority (71.9%) having received a regimen with a medium risk of developing FN, and very few had received a high-risk (12.5%) or very low-risk (15.6%) chemotherapy regimen ( Table 1 ). The majority (83%; 5/6) of patients who died had received a medium-risk FN chemotherapy regimen before hospital admission ( Table 2) .
The inpatient management costs were estimated by calculating the cost of the bed occupancy (LOS) as well as the cost of the antibiotic and G-CSF treatment received during the FN episode. For the bed occupancy alone, the mean cost for a single-patient FN episode was £2159.06. Based on an average of 13.54 DDD's of antibiotics prescribed per patient, the mean antibiotic treatment cost was £193.91 per patient. For those seven patients having also received G-CSF (at various doses), the mean cost of G-CSF was £189.29 per patient. Combining the cost of the LOS and the antibiotics treatment resulted in a crude cost of £2352.97 per patient (or £2542.26 when treatment included G-CSF) for managing an FN episode. discussion FN is a major risk factor for the development of serious infections in cancer patients. The condition has been originally described in the treatment of acute leukaemia and is a well recognised complication following chemotherapy with a significant impact on morbidity and mortality [12] . While neutropenia is more predictable in the treatment of haematological cancers, this is less so for solid malignancies. In solid tumours, chemotherapy-induced bone marrow toxicity is often an irregular and unpredictable event depending greatly 
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on a number of factors such as the chemotherapy regimen, age and disease burden. Our study has shown an overall FN incidence of ∼2% (19.4 per 1000 oncology admissions) with an attributable mortality of 12.5% among solid tumour patients admitted to the hospital. Breast cancer was the most common malignancy presenting with this condition followed by lung, oesophageal and ovarian cancer. Few published studies describe the overall incidence of FN in solid cancer patients in a day-to-day hospital oncology setting. Most available data is based on clinical trials focusing on single cancer types.
The relatively common occurrence of FN in breast cancer in our study is not surprising as studies have shown that up to 23% of women experiencing at least one episode of FN secondary to standard chemotherapy, which can increase to as much as 98% in response to certain high-dose chemotherapy regimens [13, 14] . Although the prevalence of this particular cancer has increased over the last two decades, which may explain the relative high proportion of breast cancer patients in our study, the survival rate has improved [15] . A recent case-control study supports our observation that FN poses a low risk of mortality in breast cancers compared with others such as lung cancer [16] . Previous studies have shown an FN incidence of 12%-18% for lung cancer patients and up to 49% for oesophageal cancer depending on the type of chemotherapy used [17, 18] . Surprisingly, despite the general poor prognosis of oesophageal cancer with a 5-year mortality exceeding up to 90%, no FN death took place during our study, whereas a 20% mortality was seen in lung cancer patients [19] .
The highest mortality was among brain and pancreatic malignancies, which may be due to advanced disease of the cases but equally, the low number of patients in this group may not be representative in our study.
Comparing the overall attributable mortality of patients in our investigation with cancer-associated FN studies in a similar non-clinical trial setting, our data was the same as reported by Courtney et al. [20] , whereas others reported a mortality of as low as 3.8% [21] . The difference in mortality among solid tumour patients seems to depend on the severity of FN risk, which can be measured by the MASCC risk index [7] .
On applying the MASCC index to our data, we found that patients who died had a high-risk index compared with those that survived the FN episode. This was mainly due to a higher disease burden, increased age, more severe neutropenia and presence of hypotension on admission compared with survivors. Interestingly, the type of chemotherapy regimen given before FN was only of medium (10%-20%) and not high (>20%) risk of causing FN, which may suggest that the outcome of FN is more related to patient factors described above rather than particularly aggressive chemotherapy treatment. One may also need to regularly review the indication of chemotherapy in the first instance as some patients might have already a poor performance status gaining little benefit from chemotherapy treatment.
The appropriate use of antibiotics is another crucial factor in order to minimise mortality from life-threatening infection during FN. The introduction of effective prophylactic and empirical broad-spectrum antibiotics in the management of FN has reduced the mortality from infectious causes significantly over the last four decades. Gram-negative sepsis has been reduced from 91% in the 60s to as low as 8% in recent decades [22, 23] . A number of national antibiotic guidelines for the management of FN have been published and adopted by many cancer centres [1, 24] . Our antibiotic audit has shown a good compliance with empirical antibiotic treatment involving piperacillin/tazobactam ± gentamicin, which is the most commonly prescribed combination in the UK [25] .
Nevertheless, a small number of patients in our study who had a poor outcome were prescribed different antibiotics with the intention to treat presumed pneumonia or diarrhoea. Although it is difficult to make an assumption that the higher mortality in this group was due to the lack of appropriate antibiotics for the treatment of FN, this observation suggests that all patients presenting with FN may initially be treated with empirical antibiotic for the management of FN irrespective of their clinical signs and symptoms of infection and drugs like macrolides may be added rather than prescribed exclusively.
The management of FN may further be guided by the microbiological confirmation of a causative pathogen and antimicrobial susceptibility testing but an infectious cause is often difficult to establish in neutropenic patients. We were only able to isolate an infectious agent in 16% of cases, which is even less than the one quarter of patients described in large clinical trials [2] . These low numbers of positive microbiology cultures may partially be attributed to the fact that one-fifth of our patients already received antibiotics before hospital admission or were started on antibiotics before clinical specimen sampling in order to not to delay treatment, which would have compromised microbial growth. The use of molecular techniques for the detection of pathogens in blood during antibiotic therapy may improve the diagnostic yield but currently available commercial tests are unlikely to replace microbiological culture in the near future [26] .
In view of the fact that FN remains an important clinical challenge, efforts in reducing morbidity and mortality will remain a major focus for physicians. Early recognition and classification of patients at risk is crucial in order to provide timely, targeted effective preventative or treatment measures such as G-CSF and/or antibiotic prophylaxis. Recent EORTC guidelines provide a comprehensive update on the use of G-CSF to reduce the incidence of chemotherapy-induced FN in solid tumour patients [8] . Studies have also shown that many 'low-risk' neutropenic patients can be switched safely to oral antibiotics or even managed as outpatients, which would also reduce the economic burden for health care providers [7, 27, 28] . Our study has shown that the majority of patients admitted to hospital were low-risk patients who may not have needed hospital admission.
The LOS for all FN patients was 9.2 days, which is marginally longer compared with other studies that recorded an LOS of 6.5-8.8 days [7, 20] . The cost for LOS and antibiotics combined led to an average cost of £2353 per FN episode. The actual cost is likely to be much higher as we did not include the cost of imaging or other diagnostic and additional treatment costs. Other studies have estimated costs of as much as $15 231 per FN episode or $1455/day [20, 27] .
The results of our study has since led to the local implementation of an early risk stratification policy for FN original articles Annals of Oncology patients with the aim to firstly, improved timely initiation of appropriate antibiotic and G-CSF treatment of higher FN risk patients and secondly, to encourage low-risk FN patients to be managed in the community where indicated. The latter would also improve cost-effectiveness as demonstrated by a recent study comparing low-risk outpatient versus hospital treatment [29] .
In conclusion, FN remains a serious cause of morbidity and mortality in solid cancer patients undergoing chemotherapy. Patients with a high-risk FN risk index had a worse outcome compared with low-risk patients. Particular attention should be paid to early risk stratification of FN patients with solid cancers in order to provide timely, targeted and effective preventative or treatment measures in order to improve the outcome and reduce the economic burden.
